Evidence map›Paper›PMID 42270414›Full record

ArticleJournal of peptide science : an official publication of the European Peptide Society2026

Radiolabeled Angiopep-2 Peptide Vector as a Preclinical Platform for Blood-Brain Barrier Targeting: Synthesis, Radiolabeling, and Preliminary In Vivo Biodistribution in Mice.

Evgenia Fotou, Adamantia Apostolopoulou, Christina-Georgia Bika, Maria Giannakopoulou, Danai-Efraimia Bajwa, Vassilios Moussis, Vassilios Tsikaris, Ioannis P Gerothanassis, George A Alexiou, Penelope Bouziotis and 1 more

Abstract read
In one paragraph

Article in Journal of peptide science : an official publication of the European Peptide Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Evgenia FotouSection of Organic Chemistry and Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece.
Adamantia ApostolopoulouInstitute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", Athens, Greece.
Christina-Georgia BikaSection of Organic Chemistry and Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece.
Maria GiannakopoulouNeurosurgical Institute, University of Ioannina, Ioannina, Greece.
Danai-Efraimia BajwaInstitute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", Athens, Greece.
Vassilios MoussisSection of Organic Chemistry and Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece.
Vassilios TsikarisSection of Organic Chemistry and Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece.ORCID https://orcid.org/0000-0002-2847-7340
Ioannis P GerothanassisSection of Organic Chemistry and Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece.
George A AlexiouNeurosurgical Institute, University of Ioannina, Ioannina, Greece.
Penelope BouziotisInstitute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", Athens, Greece.ORCID https://orcid.org/0000-0001-6778-2201
Andreas G TzakosSection of Organic Chemistry and Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece.ORCID https://orcid.org/0000-0001-6391-0288

Funding

European Union-NextGenerationEU TAEDK-06189/T2EDK-0326
6 · The paper itself

Abstract

Brain tumor therapy remains limited by the blood-brain barrier (BBB), which restricts drug access. BBB-penetrating peptides offer a promising strategy for delivering therapeutic and diagnostic payloads. Angiopep-2 is a well-established vector, yet novel radioconjugates based on this vector remain of interest. We report the synthesis and evaluation of DOTA-Angiopep-2 for radiolabeling with Lutetium-177 (

Indexed as

Blood-Brain BarrierBrain NeoplasmsPeptidesRadiopharmaceuticalsAnimalsCell Line, TumorHeterocyclic Compounds, 1-RingHumansLutetiumMiceRadioisotopesTissue Distribution1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidAngiopep-2Heterocyclic Compounds, 1-RingLutetiumLutetium-177PeptidesRadioisotopesRadiopharmaceuticals161Tb177LuAngiopep‐2BBBDOTAglioma targetingLRP1peptide conjugatesradiolabeling

Identifiers

PMID42270414
PMCPMC13253176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.